Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

better than the usual care treatment alone to shrink tumors in patients with stage III non-squamous non-small cell lung cancer (NSCLC). TRC102 is in a class of drugs called antineoplastic agents. It

  • 0 views
  • 05 Jul, 2022
  • 1 location
  • 0 views
  • 19 Jun, 2021
  • 30 locations
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

chemotherapy for patients with surgically resectable stage IIA - IIIB (T3-T4/N2) (based on AJCC 8th edition), non-squamous NSCLC with a KRAS p.G12C mutation. The primary objective of the study is to determine

pemetrexed
cancer
lung carcinoma
KRAS
carboplatin
  • 0 views
  • 22 Apr, 2022
  • 1 location
  • 0 views
  • 16 Sep, 2022
  • 22 locations
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

erlotinib
stage iv non-small cell lung cancer
targeted therapy
crizotinib
squamous non-small cell lung cancer
  • 14 views
  • 25 Mar, 2022
  • 9 locations
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901

To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion

cancer
measurable disease
metastasis
recurrent non-small cell lung cancer
monoclonal antibodies
  • 0 views
  • 07 May, 2021
  • 1 location
Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative NSCLC

The primary hypothesis is that camrelizumab in combination with pemetrexed/ carboplatin will present a better efficacy for treatment of first line metastatic non-squamous non-small cell lung

cancer
measurable disease
metastasis
hormone therapy
pd-l1
  • 1 views
  • 23 Jan, 2021
  • 1 location
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

-squamous non-small cell lung cancer

squamous non-small cell lung cancer
pemetrexed
osimertinib
lung carcinoma
non-squamous non-small cell lung cancer
  • 0 views
  • 04 Sep, 2021
  • 1 location
Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

This is a prospective, multicenter, open-label study to observe the effect of SBRT and immunotherapy combined with Bevacizumab or not in stage IV non-squamous non-small cell lung cancer (NSCLC

  • 0 views
  • 24 May, 2021
  • 1 location
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations.

  • 0 views
  • 24 Jul, 2022
  • 5 locations